Company AB Science

AB

FR0010557264

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 19:55:00 30/07/2026 +04			5-day change	1st Jan Change
0.5310 ^EUR	-4.67%		+1.34%	-65.43%

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules

Business description: AB Science

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Number of employees: 31

Sales by Activity: AB Science

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Pharmaceuticals	1.61M	958K	970K	1.07M	1.17M

See all business segments

Geographical breakdown of sales: AB Science

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Europe	-	-	-	-	955K
outside Europe	-	-	-	-	219K

See all geographic segments

Executive Committee: AB Science

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018
Alexis Bernard PRN	Corporate Officer/Principal	-	-

See AB SCIENCE governance

Composition of the Board of Directors: AB Science

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021
Catherine Johnston-Roussillon BRD	Director/Board Member	68	27/06/2021
Guillemette Latscha BRD	Director/Board Member	-	27/06/2021
Stéphane Ledermann CHM	Chairman	-	07/07/2026

Composition of the Board of Directors

Shareholders: AB Science

Name	Stocks	%	Valuation
UBS Wealth Management SGIIC SA 0.004443 %	3,100	0.004443 %	3 137 €

Name	Stocks	%	Valuation
Friedland Gestion SAS 5.198 %	85,471	5.198 %	32 638 €

Name	Stocks	%	Valuation
Friedland Gestion SAS 4.167 %	64,103	4.167 %	20 081 €

List of AB SCIENCE shareholders

Company details: AB Science

AB Science SA

3, avenue George V

75008, Paris

+33 1 47 20 00 14

http://www.ab-science.com

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-4.67%	+1.34%	-64.31%	-86.24%	50.72M
MERCK & CO., INC.	-0.44%	-0.53%	+58.76%	+22.05%	322B
MERCK KGAA	-1.55%	+2.59%	+28.35%	-10.91%	71.8B
HALOZYME THERAPEUTICS, INC.	+0.02%	+3.04%	+38.65%	+90.79%	9.88B
KYOWA KIRIN CO., LTD.	-2.81%	-1.62%	-0.83%	-5.17%	8.64B
SK BIOPHARMACEUTICALS CO., LTD.	+2.65%	+1.04%	-23.09%	-5.02%	4.08B
YUHAN CORPORATION	+5.26%	+5.41%	-38.54%	+12.12%	3.61B
BETTA PHARMACEUTICALS CO., LTD.	-3.86%	-8.18%	-12.14%	-2.26%	3.61B
SUPERNUS PHARMACEUTICALS, INC.	-2.06%	-3.35%	+35.91%	+49.93%	2.7B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.68%	+4.52%	-4.75%	-5.33%	2.24B
Average	-0.81%	+1.81%	+1.80%	+6.00%	42.86B
Weighted average by Cap.	-0.63%	+4.47%	+49.32%	+17.04%